In contrast to patients with colorectal cancers [16], patients with sporadic MSI MLH1 methylated endometrial carcinomas do not benefit from additional testing for V600E mutation of the BRAF gene as less than 1% display this mutation [17, 55]. This evidence concerns the gene BRAF and endometrial carcinoma.